Bavarian Nordic: Covid-19 vaccine beats Pfizer's on several parameters

Moods are bright at Bavarian Nordic after data from the first human trials of the company's Covid-19 vaccine candidate, ABNCoV2, confirm that Bavarian is holding a well-tolerated inoculation, showing higher antibody levels than approved vaccines from firms like Pfizer and partner Biontech, says Bavarian Nordic Vice President of Investor Relations & Communications Rolf Sass Sørensen.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app